RZLT

Rezolute Inc. (RZLT) | Rumor.io

Rezolute

RZLT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,259

Bullish sentiment (50-day avg)97%

Price to earnings ratio-4.24

Market capitalization404.3M

Earnings per share-0.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-74.4M

Social

What share of all stock conversation is about RZLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% +0

Jun 3

Rezolute, Inc. ($RZLT) presented Phase 3 results for its drug Ersodetug, showing strong efficacy in reducing IV glucose needs in rare tumor HI.
Analysts have raised their price targets for $RZLT, with some upgrading to "Buy" and increasing their target prices.
The company's Phase 3 results have been met with bullish sentiment, with some analysts predicting a positive final readout and others noting the potential for a significant increase in the stock price.

Generated by AI

Sentiment

Of the messages about RZLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +12.5	86.27% -11.49
Bearish	0%	0%	0% -12.5	13.73% +11.49

Bullish· Mar 25

The short interest ratio for $RZLT is high at 9.6 days, with 20.67% of the float short, potentially trapping shorts and fueling the upward move.
Institutional ownership of $RZLT is exceptionally high at 94.46%, limiting the availability of shares for shorts to buy back and intensifying the squeeze pressure.
Wedbush upgraded $RZLT from Neutral to Outperform, raising the price target from $2 to $5, following a Type B meeting with the FDA to discuss the regulatory pathway for ersodetug in congenital hyperinsulinism.

Bearish· Dec 15

$RZLT is overpriced, with one commenter suggesting it should be at least $4, implying a significant undervaluation.
Short sellers have targeted $RZLT, with multiple posts suggesting the stock is "overbought" and ripe for a short attack, leading to significant price drops.
$RZLT's financial situation is precarious, with one commenter stating the company is "bankrupt" and lacks the necessary resources to sustain itself, while another suggests the company's costs outweigh its potential benefits.

Generated by AI

Topics

Of the messages about RZLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	3.13%	8.82%	2.87%
Analysts	100%	93.75%	88.24%	1.44%
Technical Analysis	0%	0%	0%	2.3%
Earnings	0%	3.13%	2.94%	0%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	93.38%

Announcements· Jan 7

Rezolute, Inc. ($RZLT) released insights from its Phase 3 sunRIZE study in congenital hyperinsulinism, including patient characteristics and outcomes.
The company also shared findings from its Expanded Access Program in tumor hyperinsulinism, providing cumulative data from 9 participants.
Rezolute's sunRIZE trial for congenital HI failed to meet primary and secondary endpoints, shaping the development path and investor confidence.

Technical Analysis· Jan 7

$RZLT may be breaking a downtrend based on recent price action.
The trendline on $RZLT is being closely watched for potential price movement.
Technical analysis of $RZLT suggests a possible trend reversal.

Generated by AI

Community

Of the messages about RZLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	73.33%	28.57%	41.67%	5.66%
Newcomers	26.67%	71.43%	58.33%	94.34%

Regulars· Jun 14

Rezolute, Inc. is experiencing a significant pre-market drop of -18.99%, with shares tumbling 22.7% in value.
The company's Chief Medical Officer, Roberts Brian Kenneth, has increased their ownership by 12.43% after purchasing 7.6k shares for $29.7k.
Rezolute, Inc. has successfully raised $60 million in a public offering, priced at $4 per share, and is now poised to develop transformative rare disease therapies.

Newcomers· Mar 25

The newcomer is focused on the parabolic continuation potential of $RZLT, highlighting the stock's potential for significant volatility.
The newcomer is expecting major volatility in the stock, advising caution and emphasizing the importance of having a risk management plan in place.
The newcomer notes that Wedbush has upgraded the stock from Neutral to Outperform and raised its price target from $2 to $5, contributing to the stock's upward movement.

Generated by AI

News

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset

19d agoSeeking Alpha

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Also Discussed

Investors talking about RZLT also mention

#	Name	Attention
1	Zenas BioPharma, Inc.ZBIO	0%0
2	Grace Therapeutics, Inc.GRCE	0%new
3	Edgewise Therapeutics Inc.EWTX	0%new
4	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
5	Mineralys Therapeutics, Inc.MLYS	0%+0
6	Gossamer Bio Inc.GOSS	0%+0
7	Janux Therapeutics, Inc.JANX	0%0
8	Empire Petroleum CorporationEP	0%0
9	Harte Hanks Inc.HHS	0%new
10	PodcastOne, Inc. Common StockPODC	0%0

Rezolute Inc.

Healthcare
Biotechnology

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism. The company’s pipeline also includes additional candidates aimed at conditions such as diabetic macular edema, reflecting a broader focus on endocrine and metabolic disorders. Rezolute Inc. works at the intersection of rare disease research and targeted drug development, with its programs designed to address serious conditions that have limited treatment options. Based in Redwood City, California, the company plays a specialized role in the biopharmaceutical market by advancing therapies for ultra-rare pediatric and metabolic diseases.

Website

Location

275 Shoreline Drive

Redwood City, CA, 94065

United States

Social

What share of all stock conversation is about RZLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% +0

Jun 3

Rezolute, Inc. ($RZLT) presented Phase 3 results for its drug Ersodetug, showing strong efficacy in reducing IV glucose needs in rare tumor HI.
Analysts have raised their price targets for $RZLT, with some upgrading to "Buy" and increasing their target prices.
The company's Phase 3 results have been met with bullish sentiment, with some analysts predicting a positive final readout and others noting the potential for a significant increase in the stock price.

Generated by AI

Sentiment

Of the messages about RZLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +12.5	86.27% -11.49
Bearish	0%	0%	0% -12.5	13.73% +11.49

Bullish· Mar 25

The short interest ratio for $RZLT is high at 9.6 days, with 20.67% of the float short, potentially trapping shorts and fueling the upward move.
Institutional ownership of $RZLT is exceptionally high at 94.46%, limiting the availability of shares for shorts to buy back and intensifying the squeeze pressure.
Wedbush upgraded $RZLT from Neutral to Outperform, raising the price target from $2 to $5, following a Type B meeting with the FDA to discuss the regulatory pathway for ersodetug in congenital hyperinsulinism.

Bearish· Dec 15

$RZLT is overpriced, with one commenter suggesting it should be at least $4, implying a significant undervaluation.
Short sellers have targeted $RZLT, with multiple posts suggesting the stock is "overbought" and ripe for a short attack, leading to significant price drops.
$RZLT's financial situation is precarious, with one commenter stating the company is "bankrupt" and lacks the necessary resources to sustain itself, while another suggests the company's costs outweigh its potential benefits.

Generated by AI

Topics

Of the messages about RZLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	3.13%	8.82%	2.87%
Analysts	100%	93.75%	88.24%	1.44%
Technical Analysis	0%	0%	0%	2.3%
Earnings	0%	3.13%	2.94%	0%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	93.38%

Announcements· Jan 7

Rezolute, Inc. ($RZLT) released insights from its Phase 3 sunRIZE study in congenital hyperinsulinism, including patient characteristics and outcomes.
The company also shared findings from its Expanded Access Program in tumor hyperinsulinism, providing cumulative data from 9 participants.
Rezolute's sunRIZE trial for congenital HI failed to meet primary and secondary endpoints, shaping the development path and investor confidence.

Technical Analysis· Jan 7

$RZLT may be breaking a downtrend based on recent price action.
The trendline on $RZLT is being closely watched for potential price movement.
Technical analysis of $RZLT suggests a possible trend reversal.

Generated by AI

Community

Of the messages about RZLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	73.33%	28.57%	41.67%	5.66%
Newcomers	26.67%	71.43%	58.33%	94.34%

Regulars· Jun 14

Rezolute, Inc. is experiencing a significant pre-market drop of -18.99%, with shares tumbling 22.7% in value.
The company's Chief Medical Officer, Roberts Brian Kenneth, has increased their ownership by 12.43% after purchasing 7.6k shares for $29.7k.
Rezolute, Inc. has successfully raised $60 million in a public offering, priced at $4 per share, and is now poised to develop transformative rare disease therapies.

Newcomers· Mar 25

The newcomer is focused on the parabolic continuation potential of $RZLT, highlighting the stock's potential for significant volatility.
The newcomer is expecting major volatility in the stock, advising caution and emphasizing the importance of having a risk management plan in place.
The newcomer notes that Wedbush has upgraded the stock from Neutral to Outperform and raised its price target from $2 to $5, contributing to the stock's upward movement.

Generated by AI

Rezolute

Social

Jun 3

Bullish· Mar 25

Bearish· Dec 15

Announcements· Jan 7

Technical Analysis· Jan 7

Regulars· Jun 14

Newcomers· Mar 25

Rezolute stock rating upgraded to Buy at Craig-Hallum on trial data

H.C. Wainwright raises Rezolute stock price target on trial data

Citizens reiterates Rezolute stock rating on tumor trial results due

Rezolute Fiscal Q4 Loss Narrows

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset

Wall Street Analysts Are Bullish on Top Healthcare Picks

Also Discussed

Rezolute Inc.

Company Information

Location

Rezolute stock rating upgraded to Buy at Craig-Hallum on trial data

H.C. Wainwright raises Rezolute stock price target on trial data

Citizens reiterates Rezolute stock rating on tumor trial results due

Rezolute Fiscal Q4 Loss Narrows

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset

Wall Street Analysts Are Bullish on Top Healthcare Picks

Also Discussed

Social

Jun 3

Bullish· Mar 25

Bearish· Dec 15

Announcements· Jan 7

Technical Analysis· Jan 7

Regulars· Jun 14

Newcomers· Mar 25